Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Oct 23;15(10):e0241212. doi: 10.1371/journal.pone.0241212

Insights into the genetic diversity, recombination, and systemic infections with evidence of intracellular maturation of hepadnavirus in cats

Chutchai Piewbang 1,2, Sabrina Wahyu Wardhani 2,3, Surangkanang Chaiyasak 4, Jakarwan Yostawonkul 3,5, Poowadon Chai-in 5, Suwimon Boonrungsiman 5, Tanit Kasantikul 6, Somporn Techangamsuwan 1,2,*
Editor: Haitao Guo7
PMCID: PMC7584178  PMID: 33095800

Abstract

Hepatitis B virus (HBV) is a human pathogen of global concern, while a high diversity of viruses related to HBV have been discovered in other animals during the last decade. Recently, the novel mammalian hepadnavirus, tentatively named domestic cat hepadnavirus (DCH), was detected in an immunocompromised cat. Herein, a collection of 209 cat sera and 15 hepato-diseased cats were screened for DCH using PCR, resulting in 12.4% and 20% positivity in the tested sera and necropsied cats, respectively. Among the DCH-positive sera, a significantly high level of co-detection with retroviral infection was found, with the highest proportion being co-detection with feline immunodeficiency virus (FIV). Full-length genome characterization of DCH revealed the genetic diversity between the nine Thai DCH sequences obtained, and that they phylogenetically formed three distinct monophyletic clades. A putative DCH recombinant strain was found, suggesting a possible role of recombination in DCH evolution. Additionally, quantitative PCR was used to determine the viral copy number in various organs of the DCH-moribund cats, while the pathological findings were compared to the viral localization in hepatocytes, adjacent to areas of hepatic fibrosis, by immunohistochemical (IHC) and western blot analysis. In addition to the liver, positive-DCH immunoreactivity was found in various other organs, including kidneys, lung, heart, intestine, brain, and lymph nodes, providing evidence of systemic infection. Ultrastructure of infected cells revealed electron-dense particles in the nucleus and cytoplasm of hepatocytes, bronchial epithelial cells, and fibroblasts. We propose the intracellular development mechanism of this virus. Although the definitive roles of pathogenicity of DCH remains undetermined, a contributory role of the virus associated with systemic diseases is possible.

Introduction

For several centuries, blood-transfused recipients had the risk of suffering from post-transfusion hepatitis from an unknown cause, resulting in further investigation of the pathogen associated with this scenario [1]. The subsequent discovery of a hepadnaviral genome, named as human hepatitis B virus (HBV), was an important breakthrough towards enhancing global health concerns by facilitating the establishment of a blood-screening protocol prior to transfusion [2, 3]. The recognition of HBV in the blood of infected humans lead to the further discovery of HBV-like viruses in other animals, not only in mammals but also in avian and fish species [4, 5]. Recently, during transcriptomics studies of an Australian leukemia cat infected with feline immunodeficiency virus (FIV), a novel hepadnavirus, named domestic cat hepadnavirus (DCH), was detected. This merits further study of its natural history, epidemiology, and potential pathogenic roles in domesticated cats [6].

The DCH is a partially double stranded, circular, small DNA virus belonging to the Orthohepadnavirus genus, Hepadnaviridae family. It has a genome of approximately 3.2 kb of compact DNA, which encodes in four overlapping open reading frames (ORFs) for the polymerase (L), surface (S), core (C), and X proteins, similar to other hepadnaviruses. The three available genome sequences derived from DCH-positive domestic cats in Australia [6], Italy [7], and Malaysia (GenBank accession no. MK902920), show 97.0–98.3% nucleotide similarity to each other. Further identification and genetic characterization of DCH in these and other regions is required for fundamental information regarding the geographical distribution and evolution of this HBV-like virus in cats.

Since the first identification of DCH in a FIV-positive cat in Australia in 2016, surveys of DCH prevalence in cat sera were conducting in Australian and Italian domestic cats, and revealed 6.5% and 10.8% DCH positive cats with active viremia [6, 7]. Interestingly, there is a correlation between DCH-positive cats with suspected clinical symptoms of infectious diseases, particularly in cats with evidence of liver damage [7]. This finding indirectly supported the possible role of the DCH-induced feline liver disease, similar to the nature of the HBV infection in humans that is associated with chronic hepatitis and contributes to hepatocellular carcinoma (HCC) development. This hypothesis was authenticated by a recent international, multicenter, retrospective investigation of DCH in 71 formalin-fixed, paraffin-embedded (FFPE) biopsies from cats with selected liver diseases in specimens obtained from multiple continents, including USA, Australia, New Zealand, and UK [8]. The results revealed a high detection rate of DCH (43%) in chronic hepatitis cats and 28% in HCC cats, while bile duct associated diseases and normal histological livers showed PCR negative tests. Furthermore, DCH localization was observed by in situ hybridization in areas of histologically-determined liver inflammation and neoplasia. Together, these support the relatedness between the presence of DCH and feline liver diseases.

However, neither the viral tropism nor the distribution of the DCH in the other organs of infected cats has yet been investigated, and due to the limited studies of DCH biology, and so the degree of tissue tropism, whether there is any correlation between viral replication and liver damage throughout systemic infections, and the genetic diversity of DCH have all yet to be elucidated. The pathobiology of DCH infections in cats needs further determination in order to better understand its DCH infective pattern, and the identification of which organs support DCH, to elucidate viral shedding and transmission. Epidemiological data are also required to facilitate the design of prevention strategies for feline healthcare.

Therefore, we comprehensively investigated the presence of the DCH in randomized cat sera using conventional PCR and described postmortem findings through viral distribution, tissue localization, and viral loads of DCH-positive cats using quantitative (q)PCR and immunohistochemistry (IHC). Transmission electron microscopy (TEM) was used to confirm the presence of viral particles in the liver and lungs with possible reference to virus maturation and the shedding process. Genetic analysis, based on the full-length genome, revealed that genetic diversity and novel genetic clades of DCH are now circulating in the cat population in Thailand. Possible roles of systemic infections with ultrastructural localization of DCH were also addressed.

Materials and methods

Animals and samples

In total, 209 randomized domestic cats, which had visited veterinary hospitals and healthcare services in Thailand during December 2016 to December 2019, were enrolled in this study. Serum samples were collected and kept at -80 0C for further investigation. Essential signalments, including sex and age, were also recorded for further interpretation. Each cat’s age was categorized into one of the five groups of: kittens (0–6 months), junior (7 month–2 y), adult (3–6 y), mature (7–10 y), and senior (≥ 11 y), according to the life stage classification of The American Animal Hospital Association guideline [9].

Fifteen domestic cats, naturally moribund from hepatic-associated diseases, submitted for routine necropsy at Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University during November 2019 to January 2020, also were included. Selected tissue samples, including the brain, heart, intestines, kidneys, liver, lung, lymph node, and spleen, were collected, immersed in 10% (v/v) neutral buffered formalin, and submitted for histopathological processes within a few consecutive days. Sections were stained for Hematoxylin and Eosin (H&E) and Masson-Trichrome. Microscopic evaluations were performed by an American board-certified veterinary pathologist (TK). Fresh tissues, including heart, intestines, kidneys, liver, lung, spleen, and urinary bladder, were additionally collected for further analysis. All procedures were performed in accordance with the guidelines and regulations following the approval of the Chulalongkorn University Animal Care and Use Committee (No. 1931036). The cat’s owners gave their written consent for sample collection and data for this study.

Viral nucleic acid extraction and selected molecular virology tests

Serum samples from 209 living cats and homogenized fresh tissues from the 15 necropsied cats were individually extracted for total viral nucleic acids using a commercial extraction kit (Geneaid, Taipei, Taiwan). The quality and quantity of the extracted total nucleic acids were determined using a spectrophotometer to measure the A260/A280 ratio (NanoDrop, Thermo Scientific™, USA), and then kept at -80 0C. Known feline retrovirus DNA, which are feline leukemia virus (FeLV) and FIV, were initially screened using PCR assays as previously described [10]. Furthermore, pan-family virologic PCR panels for detections of bocaviruses [11], caliciviruses [12], coronaviruses [13], herpesviruses [14], paramyxoviruses [15, 16], and parvoviruses [17] were tested on fresh tissue samples from necropsied cats (as mentioned above).

Hepadnaviral screening in sera and viral load quantification in fresh tissues

The presence of hepadnavirus in the serum and fresh tissue samples was screened for by conventional PCR using primers specific for pan-hepadnaviral family as previously described [5]. Subsequently, the pan-hepadnaviral PCR positive samples were subjected to another conventional PCR for specific DCH amplification [6]. PCR products were subsequently visualized by running on the QIAxcel capillary electrophoresis (QCES) platform using a QIAxcel DNA Screening Kit (Qiagen, Hilden, Germany) with the previously reported setting and analysis [18]. The positive amplicons, either from the pan-hepadnaviral PCR or DCH-specific PCR, were then purified using NucleoSpin® Extract II kit (Macherey-Nagel, Düren, Germany) and further submitted for commercial bi-directional Sanger sequencing (Macrogen Inc., Incheon, South Korea) to confirm the specificity of the PCR results.

To quantify the DCH loads, fresh tissues of moribund cats that were previously found to be positive by PCR were further assayed using KAPA SYBR® Fast qPCR Master Mix (2X) Universal kit (KAPABIOSYSTEMS, Sigma-Aldrich, South Africa) with the designed DCH-specific primers [7]. Briefly, 5 μL of extracted DNA (from 1 g of tissue) were added into the 25-μL reaction master mix, containing 200 nM of each primer and 2.5 mM of MgCl2. The qPCR reaction was performed in a Rotor-Gene Q real-time PCR cycler (Qiagen GmbH, Hilden, Germany) with thermal cycling as 40 cycles of 95°C for 3 s and 60°C for 20 s acquiring the fluorescence A green. The software reported the cycling A green and melt A green compared with the synthesized positive control: a standard plasmid (TOPO™ TA Cloning™ Kit for Sequencing with One Shot™ TOP10 Chemically Competent E. Coli) (Invitrogen, MA, USA) containing the designed 700-bp fragment of the L gene of the three available DCH reference sequences (GenBank accession nos. MH307930, MK117078, and MK902920). The DCH copy number in each sample was calculated on the basis of standard curve calculation generated from 10-fold dilutions of the plasmid.

Full-length genome characterization and phylogenetic analysis of detected DCH

To characterize the detected DCH strains in the Thai cat population, PCR products derived from six positive serum samples and three moribund cats were submitted for full-length genome sequencing using multiple gel-based PCR amplifications and primer sets as described previously [6], plus the new primers designed from alignment of the available DCH sequences deposited in GenBank (S1 Table and S1 File). The PCR products were submitted for standard Sanger sequencing after visualization in 2% (w/v) agarose gel electrophoresis.

All derived sequences were aligned to the published DCH strains, then assembled and used to construct the full-length genome using BioEdit version 7.0.5.3. Moreover, to assure the correctness of the initial alignment, the derived DCH Thai strains were further aligned with the published DCH strains using the MAFFT sequence alignment program version 7. The sequences of the nine obtained Thai DCH strains were then compared with the three available DCH strains using a pairwise nucleotide identity matrix software embedded in BioEdit. Phylogenetic analysis of full-length DCH genomes and related hepadnaviruses reported in various species were constructed using the maximum likelihood (ML) algorithm with the general-time-reversible (GTR) model, derived from find-best-fit model analysis based on Bayesian Information Criterion (BIC) of nucleotide substitution in MEGA 7 software package. Phylogenetic trees of full-length genome sequence of Thai DCH strains were constructed with 1,000 bootstrapping replicates using MEGA 7.

Recombination in Thai DCH strains

To explore the role of genetic recombination in the evolution of DCH diversity, a dataset of alignments of all published full-length DCH genomes and those obtained in this study were examined using the various recombination detection methods. The dataset was initially screened for recombination events using the Genetic Algorithm for Recombination Detection (GARD) software [19] as a pre-processing step for selection of interference. The positive recombination sequences were then further examined using the incorporated recombination detection program 4 (RDP4) package v. Beta 4.94 software [20], which included a range of recombination detection methods: i.e. Bootscan, Chimera, GeneConv, MaxChi, RDP, SiScan, and 3 Seq. In all cases, a cut-off p-value of 0.01 and a default setting of Bonferroni correction were used. Due to the high sensitivity of these methods and the abundant signals detected during testing, only sequences that showed a positive recombination event in at least four methods were considered as potential recombination strains. The potential recombination strains identified in the RDP with its major and minor putative parents used as a query sequence, were then subjected to further confirmation of the recombination breakpoint using the similarity plot and bootscaning analysis embedded in the SimPlot software package v. 3.5.1 [21]. The similarity plot and bootscaning analysis were performed with a window and step sizes of 200 bp and 20 bp, respectively. The recombination breakpoints were detected and evaluated by the Kimura-2 parameter (K2P) and the GapStrip models for bootscan analysis similarity plot, respectively [12].

Cellular and tissue localizations of DCH using IHC

To display the tissue tropism of the DCH, the three necropsied cats that were positive in both the conventional and qPCRs specific for DCH were then subjected to this IHC-based study. The available FFPE tissues derived from these cats, including the brain, lung, liver, lymph node, spleen, heart, kidneys, and intestine, were used for DCH-tissue identification using a horseradish peroxidase (HRP) polymer-conjugated method. The 4-μm-thick FFPE sections were deparaffinized, rehydrated, and subsequently pre-treated by autoclaving at 121 oC in Tris-EDTA buffer, pH 9.0 for 30 min. The slides were then treated with 3% (w/w) hydrogen peroxide (H2O2) and 5% (w/v) skim milk in 1% PBS to block any endogenous peroxidase activity and non-specific reactions. Treated sections were then incubated with a 1:8000 dilution of rabbit polyclonal anti-human HBV core (C) antigen (HBcAg; B0586, DAKO, Glostrup, Denmark) at 4 oC overnight in a moist chamber. After triple washes, the sections were incubated with the EnViSion system as per the manufacturer’s recommendations, and subsequently immersed in 3,3'-diaminobenzidine (DAB) and counterstained with Mayer's hematoxylin. A known HBV infected-liver biopsy section from human (kindly provided by Institute of Pathology, Department of Medical Services, Ministry of Public Health) served as a positive control. Incubation with normal rabbit IgG antibody NI01 (Sigma-Aldrich, MO, USA) and no-primary antibody stained incubation slides served as negative controls. Additionally, to further support the results of the manual IHC analysis, an automated IHC with different antigen retrieval and endogenous peroxidase blocking methods was performed on these sections, as detailed in S2 File.

Western blotting of anti-HBcAg antibody with the DCH

The cross-reactivity of anti-HBcAg antibody against DCH protein was elucidated by western blotting. Liver samples of three DCH-positive cats (CP1N-CP3N) were subjected for protein extraction using RIPA Lysis and Extraction buffer (Thermo Scientific™, USA) following manufacturer’s suggestions. The extracted proteins were calculated using Pierce™ BCA Protein Assay kit (Thermo Scientific™, USA) and adjusted to 5 μg/μL with the lysis buffer. The western blotting was performed as previously described with some modifications [22]. Briefly, proteins (125 μg/well) were separated by SDS-PAGE using 12% polyacrylamide gels, electrophoretically transferred to a nitrocellulose membrane, and blocked with 5% skim milk in Tris-buffered saline for 2 h. The proteins were then incubated with the anti-HBcAg antibody (1:2,000; HBcAg; B0586, DAKO, Glostrup, Denmark) for overnight at 4 oC. Bound reactivity was determined by using horseradish peroxidase (HRP)-labeled secondary antibodies (1:10,000; goat anti-rabbit IgG secondary antibody; ab205718, Abcam, Cambridge, UK) for 2 h at room temperature. The proteins of interest were visualized with ECL western blotting detection reagents (GE Healthcare) and the western blot imaging was performed using a Pop-Bio Vü Imaging System (Pop-Bio Imaging, Cambridge, UK). HBV-infected human liver (no. 158-liver; kindly provided by the Research Unit of Hepatitis and Liver Cancer of Chulalongkorn University, Bangkok, Thailand) was served as a positive control while two liver samples derived from DCH PCR-negative cats with and without histological evidences of hepatitis (nos. 045- and 046-liver, respectively) were served as negative controls.

Ultrastructure of DCH-infected tissues using TEM

In order to ultra-structurally demonstrate the DCH-viral particles in the cat’s tissues, the FFPE sections of the liver and lung from a necropsied cat (cat no. 3) that was DCH-positive in both the PCR and IHC analyses, were subjected to TEM analysis. The TEM samples were prepared from histological slides with double heavy metal staining [23, 24] and pop-off techniques with modifications [25, 26]. Briefly, histological slides were deparaffinized in 100% xylene to dissolve all the paraffin wax, washed in absolute ethanol twice, and then rehydrated in a graded decreasing concentration of ethanol [100 to 70% (v/v)] in deionized water (dH2O). Afterwards, the sections were bulk-stained in staining solution containing 2% (v/v) osmium tetroxide (Electron Microscopy Sciences EMS, PA, USA), 1.5% (w/v) potassium ferrocyanide (Sigma Aldrich, MO, USA), and 2 mM CaCl2 in dH2O for 1 h and then washed in dH2O. Subsequently, the sections were immersed in 0.5% (w/v) thiocarbohydrazide solution (Sigma Aldrich, MO, USA) in dH2O for 20 min, followed by 2.0% (v/v) OsO4 in dH2O for 30 min at room temperature. The sections were then immersed overnight in a solution of 0.15 M gadolinium acetate and 0.15 M samarium acetate (Sigma Aldrich, MO, USA), washed twice in dH2O, and incubated in 1% Walton’s lead aspartate at 60 0C for 30 min [27, 28] to enhance the contrast. Sections were then dehydrated in a graded [70 to 100% (v/v)] ethanol concentration in dH2O. The sections were infiltrated with Epon 812 (Electron Microscopy Sciences EMS, PA, USA) and then placed upside down on top of molding capsules and polymerized at 70 0C overnight. The sections were then cracked and removed from glass slide via the pop-off technique. The ultrathin sections were cut and collected using an ultra-microtome (EM UC7, Leica Microsystem, PA, USA). The ultrastructure was investigated using TEM (HT7800; Hitachi, Tokyo, Japan) operated at 80 kV.

Statistical analysis

All categorical variables were analyzed among groups by Fisher’s exact test or the χ2 test with Yates correction. All tests were two-sided, and a p-value of < 0.05 was considered to indicate statistical significance. The statistical analyses were performed using the GraphPad Prism 8 and Microsoft Excel for Microsoft Office 365 software.

Results

Detection of DCH in cat serum and liver

A total of 209 serum samples were randomly enrolled in this investigation. Eighty-seven subjects (41.6%) were male, and 122 (58.4%) were female; the mean age (± SD) was 3.7 ± 2.7 y, and the median age was 3 y (range: 1 month– 13 y). Among 209 sera, 26 (12.4%) sera were positive to both pan-hepadnaviral PCR and DCH-specific PCR methods. In addition, 15 (57.7%) DCH-positive cats were positive for FIV, 3 (11.5%) DCH-positive cats were individually positive to FeLV. while only one (3.8%) DCH-positive serum was positive to both FIV and FeLV DNA PCRs. There were significant differences in the co-detection of feline retroviruses (p = 0.017), with the highest significance for FIV co-detection (p < 0.00001). However, the sex and age of cats were not significantly associated with DCH infections. All DCH-PCR positive samples were further sequenced and confirmed for the presence of a partial fragment of the DCH genome.

For DCH detection in necropsied cats, 15 fresh liver samples derived from 15 moribund cats showing macroscopic lesions in liver were included in this study. Nine moribund cats were male, and six were female, with a mean age of 3.3 ± 1.7 y. Of these 15 cats, three (20%; two males and one female; mean age of 3.1 ± 0.8) were positive with pan-hepadnavirus and DCH-specific PCRs, and confirmed to be DCH by Sanger sequencing.

Genetic diversity, phylogeny, and genetic recombination of DCH circulating in Thai cats

After reconstruction of the whole DCH genome detected in this study, the coding sequence of the Thai DCH strains was found to be comprised of four main ORFs that encoded for the L, S, C and X proteins and formed an approximately 3.2 kb long circular viral DNA structure. The full-length genome sequences of the six Thai DCH strains derived from cat sera were named as DCH isolates CP23S THA/2016, CP54S THA/2016, CP15H THA/2019, CP79H THA/2019, CP87H THA/2019, and CP99H THA/2019 (GenBank accession nos. MT506039, MT506040, MT506042–MT506045), while the three Thai DCH strains from moribund cats were named CP1N-THA/2019¸ CP2N-THA/2019, and CP3N-THA/2019 (GenBank accession nos. MT506041, MT506046, and MT506047), respectively. Nucleotide pairwise identity revealed that all the Thai DCH strains showed genetic diversity amongst themselves, and a 96.0–98.5% nucleotide similarity amongst the other three strains from other countries, with the highest similarity to the DCH strain from Malaysia (UPM CHV04; MK902920) and the lowest to the Australian DCH (Sydney 2016; MH307930). Interestingly, the majority of Thai DCH strains were divergent and formed novel phylogenetic lineages, separating the phylogenetic tree of DCH strains into three major clades, tentatively named as genotypic groups A to C in this study (Fig 1). The phylogenetic topology separated the previously published DCH and two of the Thai DCH strains (CP2N THA/2019 and CP3N THA/2019) into group A, while the remainder of the Thai strains additionally clustered into two different lineages, groups B and C.

Fig 1. ML phylogenetic tree showing the genetic relationship of the full-length coding DCH genomes.

Fig 1

The ML tree was constructed using the GTR model and 1,000 bootstrapping. Bootstrap values (%) are shown above nodes when > 50%). Reference sequences used in this analysis are indicated with their respective GenBank accession nos. The DCHs were clustered with mammalian hepadnaviruses, while the avian and fish hepadnavirus sequences served as outgroups. The phylogenetic tree of DCH revealed three different phylogenetic clades (Groups A–C) with high bootstrap support (95–100%). The Thai DCH strains detected in this study are indicated by a red triangle (Inset).

Initial use of GARD suggested that there were genetic recombination events in the data set of DCH alignments. This prompted us to further elucidate the recombination events using multiple statistically analytical programs embedded in the RDP4 software to identify the possible potential recombination breakpoint. The recombination breakpoints were identified in the viral C protein of DCH strain CP23S THA/2016 (genotype C) that were supported by statistical algorithms including GENECONV, BootScan, Maxchi, Chimaera, and 3Seq with a p-value of 4.398 x 10−7, 4.915 x 10−5, 5.833 x 10−4, 1.523 x 10−2, and 2.785 x 10−5, respectively. The recombinant CP23S THA/2016 strain had a DCH strain CP54S THA/2016 (genotype C) and a DCH strain Sydney2016; MH307930 (genotype A) derived from an Australian cat as its putative major and minor parents (Fig 2A). The DCH CP23S THA/2016 strain was assured as recombinant strain by a positive recombination breakpoint in the similarity plot and bootscaning analyses, suggesting that it had the high nucleotide similarity to the DCH strain CP54S THA/2016 (blue line), but also had nucleotide identity to the DCH strain Sydney2016 (red line) at the middle of viral core protein gene (Fig 2B). The putative recombination breakpoint was identified at the location of 1,980–2,178 nt of the C protein gene. The potential recombination event was also confirmed by phylogenetic tree construction of different genome segments (Fig 2C).

Fig 2. Schematic diagram of the recombinant DCH CP23S THA/2016 strain.

Fig 2

(A) The DCH CP54S THA/2016 isolated in this study and DCH Sydney2016 (MH307903) from Australia served as the putative major and minor parents. (B) The potential recombination event was detected in the core protein gene and was supported by similarity and bootscan analysis, which indicated that DCH CP54S THA/2016 (blue line) served as the main template of the whole DCH genome, and then the genome sequence was replaced by the sequence from the DCH Sydney2016 at most of the C gene. The DCH CP23S/2016 isolate served as the query. The y-axis indicated the percentage of nucleotide identity and permutated trees for the similarity plot and boot scanning, respectively, within a 200 bp-wide window with a 20-bp step size between plots. (C) The ML phylogenetic trees of the recombinant DCH23S THA/2016 strains (●) and its major (▲) and minor (▼) putative parent strains over three different segments. Bootstrap (1000 replications) values over 50% are shown for each node.

Viral localization and related pathological changes of DCH-positive moribund cats

Three DCH-positive necropsied cats, designated as cats no. 1 to 3, respectively, were examined. With reference to the collection of fresh tissues, the qPCR targeting for DCH was used to confirm the presence of the virus and to estimate the amount of DCH DNA in various organs. From the qPCR analysis, DCH DNA was identified in the liver, lung, kidneys, urinary bladder, and spleen in all three necropsied cats, while DCH DNA was additionally detected in the intestine of cats no. 1 and 3, and the heart for cats no. 2 and 3. The amount of DCH DNA is shown in Table 1. The presence of DCH DNA in various tissues raised the question as to whether this represented hematogenous spreading or actual viral localization. Accordingly, two independent IHC methods against the hepadnaviral C protein were used to identify the cellular tropism of DCH with respect to the related pathological changes. Overall, within several sections of three necropsied cats and IHC staining methods, the staining patterns were similar among cats.

Table 1. Copy number of DCH in different organs of three necropsied cats.

Cat no. Viral copy number (genome copies/gram of tissue)
Liver Heart Lung Intestine Kidney Urinary bladder Spleen
1 2.11 x 104 0 0.18 x 101 2.41 x 107 1.39 x 105 <1 2.63 x 107
2 1.37 x 104 2.42 x101 1.82 x 102 0 1.54 x103 <1 <1
3 1.28 x 108 1.59 x 105 9.30 x 107 1.82 x 109 5.85 x 104 <1 1.49 x 108

Postmortem examination of all three necropsied cats revealed varied degrees of systemic inflammations in various organs. Specifically, hepatitis and hepatic fibrosis were illustrated with different severities in all cats. For cats no.1 and 2, hepatocytes were diffusely rounded and dissociated, the central veins were thickened by moderate bands of fibrous connective tissue, and associated mild to moderate aggregates of hemosiderin laden macrophages, lymphocytes, and plasma cells. The liver section of cat no. 3 showed a greater severity, presented a massive surrounding of thick bands of fibrosis bridging between portal structures (Fig 3A). These dense bands of fibrosis contained high numbers of tortuous and slit-like bile ducts that were associated with increased arteriolar profiles, and specifically the centrilobular hepatocytes were variably atrophied and formed haphazard thin cords. Such pathological changes in the liver sections in all cats were governed by the positive Masson-Trichrome special staining (Fig 3A, inset), suggesting evidence of liver fibrosis. The IHC staining patterns were similar among the three cats, revealing a cytoplasmic positive signal of DCH that was strongly detected in multifocal and diffuse staining in the hepatocytes and bile duct epithelial cells, adjacent to the focal inflammation and fibrosis (Fig 3B).

Fig 3.

Fig 3

Domestic cat hepadnavirus infection of the (A, B) liver and (C, D) kidney. Representative (A, C) H&E and (B, D) DHC IHC images from cat no. 3. (A) Hepatic fibrosis with sinusoidal lymphocytic infiltration (arrowheads) plus positive staining to Masson-Trichrome special staining (inset). Bar indicates 45 μm. (B) DCH-immunoreactivity signals were indicated in cytoplasm of hepatocytes (inset) in the area adjacent to hepatic fibrosis (arrowhead). Bar indicates 170 μm. (C). Membranoproliferative glomerulonephritis with focal interstitial nephritis. Bar indicates 170 μm. (D) DCH immunopositivity was observed in the vascular pole, glomerular capillary loops and basement membrane, and mesangial cells (inset). Bars indicate 170 μm.

In the kidneys, glomerular changes in cats no. 2 and 3 were more prominent than in cat no. 1. The walls of glomerular capillaries of cats no. 2 and 3 were globally diffusely thickened by moderate hyalinized material, while the changes in the glomerular capillary walls of cat no. 1 were mild, and only segmental and multifocal. All cats revealed dense interstitial aggregates of lymphocytes and plasma cells scattered in the cortical region (Fig 3C). The renal tubules were focally replaced and effaced by a thick band of dense fibrous connective tissue containing small aggregates of hemosiderin laden macrophages and interstitial infiltrates of lymphocytes and plasma cells scattered within the renal cortex. The DCH IHC signals were observed in endothelial cells of vascular poles, glomerular capillary loops and basement membrane, and mesangial cells (Fig 3D), where membranoproliferative glomerulonephritis was evident.

For the lung, the changes varied from acute to chronic among the three cats. In cat no. 1, the lung had diffuse interstitial infiltrates of mixed leukocytes, and the alveolar lumens contained variable eosinophilic proteinaceous materials and erythrocytes-laden foamy macrophages. For cats no. 2 and 3, the alveolar interstitium was widely and multifocally expanded by thick bands of fibrosis, the smooth muscle of terminal airways was moderately hyperplastic, and the pulmonary alveolar capillaries were increased in prominence, tortuous, and markedly engorged. The subsequent collapsed alveoli were segmentally lined by plump and tombstoning type II pneumocytes that contained variable numbers of foamy histiocytes. In these regions, many bronchiolar/bronchial airways were obviously collapsed (Fig 4A), the lining epithelium varied from hyperplastic to attenuated and eroded, and there were multifocal follicular aggregates of prominent bronchial-associated lymphoid tissue noted in some areas. The DCH-immunoreactive signals were strong and diffuse staining in the cytoplasm of the bronchial and bronchiole epitheliums, lamina propria connective tissues, vascular endothelial cells, and bronchial gland epitheliums (Fig 4B).

Fig 4.

Fig 4

Domestic cat hepadnavirus infection in the (A, B) lung and (C, D) heart. Representative (A, C) H&E and (B, D) DHC IHC images from cat no. 3. (A) Severe broncho-interstitial pneumonia with collapsed bronchial airways. Bar indicates 45 μm. (B) DCH-immunoreactivity signals were clearly detected in the cytoplasm of bronchial luminal (inset) and glandular epitheliums and endothelial cells of blood vessels. Bar indicates 45 μm. (C) Multifocal cardiac necrosis revealed by the pinwheel pattern (arrowheads) and focal cardiac fibrosis. (D) DCH immunopositive-signals were detected in the cytoplasm of myocardium (inset) adjacent to the pericarditis. The endothelial cells were also immunopositive (arrowhead). Bars indicate 170 μm.

Changes in the heart were revealed as various degrees of myocardial disarray and hypertrophy among the three cats, as evidenced by the haphazard orientation of cardiac myofibers resulting in the formation of branching or radiating "pinwheel" patterns (Fig 4C). Note that for cat no. 3, the epicardium was diffusely thickened by thick bands of fibrosis and granulation tissue containing dense, dissecting, interstitial, and perivascular infiltrates of predominant neutrophils, and a few foamy histiocytes, lymphocytes, and plasma cells dissecting the plump spindloid fibroblasts. The DCH IHC signals were also detected in the myocardium, where evidence of myocardial necrosis was noticed in cat no. 3 (Fig 4D).

Within the sections of intestines and lymph nodes, the histology was similar among the three cats, with moderate lymphoplasmacytic enteritis and histiocytic lymphadenitis. The DHC immunoreactive signals were clearly evident in the cytoplasm of the cryptal epitheliums and in the endothelial cells within the lamina propria in intestinal villi (Fig 5A), as well as diffuse, generalized, intracytoplasmic staining in the histiocytes residing in the lymph nodes (Fig 5B). Although the histology of the cerebellum of necropsied cats revealed unremarkable lesions, the DCH IHC signals were evident in neurons and glia cells (Fig 5C) with moderate and diffuse staining in the endothelial cells of small blood vessels and in choroid plexus epitheliums (Fig 5D). No DCH IHC signal was detected in the negative controls (S1 Fig).

Fig 5.

Fig 5

Domestic cat hepadnavirus infection. Representative IHC images from (A, B) cat no. 2 and (C, D) cat no. 1. (A) Intestine. Immunopositive signals diffusely labelled in the cytoplasm of cryptal epithelial cells. (B) Lymph node. Histiocytes circulating in lymph node were labelled with DHC immunoreactivity. Bars indicate 45 μm and 850 μm, respectively. (C) Cerebellum. Immunoreactive signals were labelled in the cytoplasm of neurons (inset) and vascular endothelium (arrows), and in the nucleus and cytoplasm of glia cells (arrowheads). (D) Immunopositive signals were also detected at the choroid plexus and relating endotheliums. Bars indicate 45 μm and 850 μm, respectively.

Cross-reactivity of anti-HBcAg antibody with DCH

To ensure the results of DCH-IHC using anti-HBcAg antibody, the cross-reactivity of the antibody to the DCH was tested using western blotting. In this test, we compared the reactivities of the antibody towards liver tissue extracts derived from DCH PCR-positive cats (nos. CP1N-CP3N-liver) while the HBV-infected human liver extract (no. 158-liver), and DCH PCR-negative liver sample extracts (no.045-liver; hepatitis cat and no. 046-liver; non-hepatitis cat) were served as positive and negative controls, respectively. As expected, the HBV-positive sample revealed positive reactivity to the about 21 kDa protein band that the molecular weight related to HBV core protein [22, 29]. The immunoreactivity was observed in the DCH-positive samples as in the same target to the HBV core protein at the various intensity among the samples. The positive antigenic protein was absent in all DCH-negative samples (Fig 6).

Fig 6. Cross-reactivity of anti-HBcAg with the DCH.

Fig 6

Western blot analysis revealed positive reactivity of 21 kDa protein of DCH-positive liver samples (CP1N-CP3N-liver) that was similar to result of the HBV-positive sample (158-liver). No reactivity was observed in DCH-negative samples (nos. 045- and 046-liver).

Ultrastructure of DCH in tissues

To further verify the results of DCH detection in tissues using qPCR and IHC, TEM was performed on selected lung and liver FFPE samples derived from necropsied cat no. 3, confirming the presence of DCH particles. In the liver section, viral surface antigen spheres, estimated at 23–25 nm in diameter, were identified in the nucleus (Fig 7A) and/or cytoplasm (Fig 7B) of hepatocytes and some biliary ductal cells. Notably, the viral particles were occasionally observed in the nuclear membrane and they were protruding into the endoplasmic reticulum (ER), resembling a budding process (Fig 7B). The ER membrane appeared to proceed into its lumen to form an invagination, attached with the particles. The invagination continued and enveloped the particles within the wall of ER, envisaged as a particle budding process.

Fig 7. Ultrastructure of DCH and intracellular development of DCH particles in the liver.

Fig 7

Representative TEM images from the liver of cat no. 3. (A) The DCH antigen spheres (inset) were detected in the nucleus of hepatocytes. Arrows indicate the nuclear membrane. (B) Numerous DCH particles were found in the nucleus (N) with a single viral sphere inside the nuclear membrane (asterisks). A complete Dane-like particle (arrow) was observed in the cisternae of the ER and numerous incomplete Dane-like particles and viral particles were attached to the ER membrane (inset). (C) Invagination of the ER membrane with a complete Dane-like particle. Incomplete Dane-like particles stalked with the ER membrane and attached viral particles with the ER membrane were observed (arrows). The Dane-like particles were frequently observed as free-floating and attaching to the membrane (inset). (D) Numerous clusters of DCH core particles (inset) in the cytoplasm of fibrous cells residing in the area of fibrosis. Bars indicate as described in figures.

Interestingly, larger viral particles with a double membrane layer, similar to a Dane particle of the HBV, and estimated to be 42 nm in diameter, were seen in the vicinity of the ER (Fig 7B), where its cisternae were dilated and contained viral particles in some areas. Complete Dane-like particles were seen in the cisternae that contained intracisternal tubular structures, and presented as a tadpole-like appearance connecting the Dane-like particles with the tubular structures, while some incomplete Dane-like particles were noted to be attached at the ER membrane (Fig 7C). Furthermore, complete Dane-like particles were seen at the outer plasma membrane of hepatocytes and some particles were sheathed by the plasma membrane. Apart from the hepatocytes, the viral particles were frequently observed in the cytoplasm of elongated cells that were surrounded by collagen fiber, indicating these cells were fibroblasts (Fig 7D).

For the ultrastructure of lung section, the viral spheres and Dane-like particles were frequently observed. However, free viral particles were seen in the cytoplasm of bronchial epithelium (S2 Fig) and in the nucleus of bronchial gland (S3 Fig). Of note, numerous free- and clustered-viral particles were observed in the cytoplasm of fibroblastic cells. Neither viral core particles nor Dane-like particles were observed in other pulmonary cells.

Discussion

Since the first identification of DCH in a leukemia cat in 2018, further surveys of DCH in Australian and Italian cat sera revealed active DCH viremia in cats showing evidence of feline retroviral infection with increased hepatic enzyme values representing liver damage [6, 7]. These findings provided an indirect mirror on what has been seen in HBV infections in humans and hepadnaviral infections in various animals [4]. A recent retrospective study of DCH in feline FFPE-liver sections using PCR and in situ hybridization revealed hepatotropism of the virus and associations with hepatitis and HCC [8], which have been considered to be idiopathic in this species over time [30]. However, the role of DCH pathogenicity in active cases through the cellular distribution of DCH in other organs has not been elucidated. Furthermore, information regarding the genetic diversity and evolution of DCH are clearly limited, due to the fact that the DCH is a recently discovered virus, and so further investigations are needed.

In this study, we investigated the presence of DCH in randomized cat sera and found it has likely been circulating in the Thai cat population since at least 2016 (no samples prior to 2016 were tested), similar to the timeframe of the first identification of DCH [6]. Interestingly, we found a significant prevalence in the cohort of DCH-positive cats with retrovirus co-detections, with the highest significance being with FIV coinfections. These results were in accordance with previous studies that indicated most DCH-positive cats were co-detected with feline retrovirus [6, 7]. Because feline retroviruses cause impairment to the immune system [31, 32], the detection of DCH in cats simply because they are immunocompromised is possible, and is what has been recognized for HBV infection, where HBV is more prevalent in immunocompromised humans [33, 34]. Further investigation of the association of DCH with feline retroviruses is needed to elucidate this observation.

Little is known about the genetic diversity of DCH, which prompted us to study the full-length genome of randomized nine of the detected Thai DCH strains. These sequences revealed a genetic diversity among the Thai DCH strains and amongst the three previously published DCH strains from other countries, forming three separate monophyletic groups, tentatively named in this study as groups A to C. The genetic diversity of DCH, which may result from geographically distinct mutations or recombination among detected DCH strains, has also been displayed in the HBV genotype and subgenotype characteristics [35, 36]. Further investigation into the epidemiology of DCH in other regions by genetic characterization will fill this gap.

Studies on hepadnaviral evolution have indicated the role of genetic recombination in the evolution of these viruses [3739]. Therefore, we examined potential recombination in the Thai DCH strains and found one likely homologous DCH recombinant (strain CP23S THA/2016), suggesting a possible role of recombination in DCH evolution. The finding of the genetic recombination event at the C gene of DCH CP23S THA/2016 mirrors the favored position for genetic recombination in other hepadnaviruses, which are frequently observed in HBV genotypes in humans and non-human apes [37, 40]. Mixed infections are an influencing factor for genetic recombination [41, 42]. In the present study, the DCH strains (CP2N- and CP3N- THA/2019) were most closely related to DCH Sydney2016, indicating the likely origin (strain) from which the 1,980–2,178 nt region in the C gene of the recombinant DCH CP23S THA/2016 circulating in Thailand came from. Therefore, we speculated that recombination during a mixed infection was the most likely origin of this recombinant DCH strain. However, neither the mechanistic factor that influenced the recombination event nor the effects of this mutation on DCH are known.

A recent study demonstrated the association of DCH in feline hepatitis and HCC, which mirrors that of HBV [8]. However, the pathogenesis and distribution of DCH throughout different tissues was unknown. Accordingly, we described the systemic infection of DCH and associated lesions in various organs of three Thai cats. Overall, the viral localization and histological features of this DCH resembled HBV infection in humans and other hepadnavirus infections in other animals [4347]. The most consistent lesion found in DCH-positive cats by IHC was chronic active hepatitis and hepatic fibrosis, with the cytoplasmic expression of the DCH-viral C protein in hepatocytes.

Due to the fact that different staining patterns of the HBcAg IHC may reflect differences in the histological activity and viral replication [4850], the IHC staining pattern was confirmed by a second automated IHC. Together these results suggested that these necropsied cats may be at a chronic stage of the infection, supported by the histological feature of hepatic fibrosis and low DCH viral copy number in the liver. The western blot analysis revealed the presence of viral protein, indicating the expression of the virus in the liver samples of infected cats. Furthermore, the western blot analysis indicated the cross reactivity and specificity of anti-HBcAg antibody to the DCH antigen, supporting the results of IHC. Since we used the polyclonal antibody against HBV C protein to detect the immunoreactivity with the DCH, a clear state for relationship of staining pattern with the stage of infection may be subjected for specificity of this IHC and need further elucidation by using specific monoclonal antibody against DCH.

Apart from liver, we described, by qPCR and the expression of HBcAg IHC, for first time, the DCH localization in various organs and cell types outside of the liver, supporting the spectrum of extra-hepatic manifestations of the nature of hepadnaviral infections [43, 46, 51]. The different DCH viral loads among the investigated cats may support the degree of severity, as presented in HBV-infected human patients [52]. Although this resemblance between HBV and DCH is fascinating, whether a correlation also exists between DCH replication and liver damage still requires to be established. For instance, the varying DCH viral loads in different organs cannot be concluded in this study, and a further structured, larger observational study is required.

Within the glomerulonephritis, we revealed DCH infection in the renal and vascular endothelial cells, supporting that viral localization may be associated with lesions. Like HBV, which makes kidneys its potential reservoir for its replication [53, 54], the possible role of DCH-associated glomerulo-nephropathy requires consideration. Recent observations in HBV-infected humans have speculated on the possibility of HBV replication in nervous systems [44, 55]. Thus, the positive DCH immunoreactivity in the choroid plexus and endothelial cells may support the ability of DCH to cross the blood brain barrier and the possibility that DCH can replicate in these tissues, as supported by the observed DCH immunoreactivity localized in neuron and neuroglia cells.

Similar to the findings in this study, the extrahepatic biology of other hepadnaviruses in animals, including HBV in patients with chronic hepatitis [56] has revealed that various cell types, including endothelial cells, monocytes, mucosal epithelial cells, and stromal fibroblasts, can potentially harbor the virus. However, the detection of DCH material (e.g. by IHC) and actual infection of various tissues cannot be definitively claimed from these results, although they do suggest the possibility of a DCH replication site or a reservoir within these tissues. Further descriptions of DCH should now focus on the potential link to DCH replication associated with lesions to provide more information regarding any pathological lesions caused by this infection.

Within DCH associated with the diseased cats, the ultrastructure of DCH localization would not only provide a non-biased identification but also shed light on the intracellular activity of the virus [57]. Here, we described the intracellular localization and maturation of DCH particles in both liver and lung sections using TEM analysis. Similar to in the intracellular development of HBV, the presence of Dane particles in the tissue represents the complete development of the virion [58, 59]. We detected the DCH particles in the nucleus and/or cytoplasm of hepatocytes, which may suggest the initial localization of the virus as described in HBV [58, 60]. Surprisingly, we found viral particle protrusion from the nucleus into the cisternae of ER that was evidenced by coating the core particle with the ER membrane. Further evidences suggesting that the ER may be associated with DCH intracellular maturation was revealed by the attachment of incomplete Dane-like particles to the wall of the ER with stalks and the free floating of complete Dane-like particles in the cisternal cavity. Here, we schematically illustrate the possible DCH particle development in Fig 8, which is similar to that described in the maturation of HBV [58, 59] and other viruses, including rubella virus [61] and Zika virus [62].

Fig 8. Schematic representation of the cellular development of DCH.

Fig 8

The viral core particles are in the nucleus. After transcription/translation process, the DCH DNA is assembled in the cytoplasm and then buds to the ER. The process of DCH development occurs in the ER with invagination of the membrane to form tadpole-like phenomenon. The viral envelope is then developed with the activity of the ER membrane and finally transported to the plasma membrane to excrete the complete DCH virion as budding process.

Interestingly, DCH-immunopositive signals were also observed in extra-hepatic organs. This was further explored in lung sections by TEM analysis. The DCH particles were found in the bronchial gland epithelia and in fibroblast cells, which may suggest that these cells could support viral replication, as previously demonstrated in other hepadnaviral infection models [63, 64] and natural infection of the HBV associated with chronic hepatis [56]. However, this interpretation for DCH needs further experimental investigation on the DCH biology and replication for verification.

In summary, this study identified DCH in cat sera, with the highest prevalence in FIV co-detection. The nine Thai DCH strains sequenced here revealed genetic diversity within these DCH Thai strains that segregated into three novel monophyletic clades. In addition, evidence of recombination was found that may influence the evolution of DCH diversity. The hepatotropism and extra-hepatic manifestations of the virus were revealed with reference to intracellular development of DCH particles. Although the definitive role of pathogenicity of DCH remains undetermined, a contributory role of virus-associated systemic diseases is possible. Further elucidation on the influence of the virus on feline health is undoubtedly necessary.

Supporting information

S1 Raw image

(PDF)

S1 Table. The DCH-specific primers used for the full-length genome characterization.

The primers were designed based on an alignment of the three DCH genomes that were available in GenBank.

(PDF)

S1 File. Amplification protocols used for characterization of the full-length DCH genome.

The PCR amplifications were performed using the primers described in S1 Table.

(PDF)

S2 File. Automated IHC protocol for DCH detection in FFPE tissues of DCH-PCR positive moribund cats.

(PDF)

S1 Fig. Negative controls for the DCH IHC staining.

No reaction is present within an incubation of normal rabbit IgG antibody NI01control in the (A) liver, (B) kidney, (C) lung, and (D) heart sections of cat no. 3, the (E) intestine of cat no. 2, and (F) brain of cat no. 1.

(TIF)

S2 Fig. Domestic cat hepadnavirus particles in cytoplasm of the lung tissue.

Representative TEM image showing the ultrastructure of the bronchial epithelium and the diffuse electron-dense particles in the cytoplasm (inset). Bar indicates as in figure.

(TIF)

S3 Fig. Domestic cat hepadnavirus particles in nucleus of the lung tissue.

Representative TEM image showing the ultrastructure of the bronchial glandular epithelium and the focal cluster of electron-dense particles in the nucleus (inset). Bar indicates as in figure.

(TIF)

Acknowledgments

Outstanding western blotting techniques were supported by Tanida Tungchaisin and Assistant Professor Dr. Kittipong Rattanaporn, Faculty of Agro-Industry, Kasetsart University, Bangkok, Thailand.

Data Availability

DCH sequences have been deposited in NCBI GenBank under accession numbers MT506039-MT506047. All other relevant data are within the manuscript and its Supporting Information files.

Funding Statement

C.P. was supported by the Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University. S.W. is financially afforded by scholarship program for ASEAN countries, Chulalongkorn University. This research was funded by The Thailand Research Fund (RSA6180034), Grant for Joint Funding of External Research Project, Ratchadaphisek Somphot Endowment Fund and Veterinary Science Research Fund (RES_61_364_31_037), Chulalongkorn University, and Veterinary Pathogen Bank, Faculty of Veterinary Science, Chulalongkorn University.

References

  • 1.Maccallum FO. Homologous Serum Hepatitis. Proceedings of the Royal Society of Medicine. 1946;39(10):655–7. [PMC free article] [PubMed] [Google Scholar]
  • 2.Blumberg BS. Australia antigen and the biology of hepatitis B. Science. 1977;197(4298):17–25. 10.1126/science.325649 [DOI] [PubMed] [Google Scholar]
  • 3.Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66(5):924–31. 10.7326/0003-4819-66-5-924 [DOI] [PubMed] [Google Scholar]
  • 4.Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma research. 2016;2:163–86. 10.20517/2394-5079.2016.05 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang B, Yang XL, Li W, Zhu Y, Ge XY, Zhang LB, et al. Detection and genome characterization of four novel bat hepadnaviruses and a hepevirus in China. Virol J. 2017;14(1):40 10.1186/s12985-017-0706-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Aghazadeh M, Shi M, Barrs VR, McLuckie AJ, Lindsay SA, Jameson B, et al. A Novel Hepadnavirus Identified in an Immunocompromised Domestic Cat in Australia. Viruses. 2018;10(5). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lanave G, Capozza P, Diakoudi G, Catella C, Catucci L, Ghergo P, et al. Identification of hepadnavirus in the sera of cats. Sci Rep. 2019;9(1):10668 10.1038/s41598-019-47175-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pesavento PA, Jackson K, Hampson T, Munday JS, Barrs VR, Beatty JA. A Novel Hepadnavirus is Associated with Chronic Hepatitis and Hepatocellular Carcinoma in Cats. Viruses. 2019;11(10). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hoyumpa Vogt A, Rodan I, Brown M, Brown S, Buffington CA, Larue Forman MJ, et al. AAFP-AAHA: feline life stage guidelines. J Feline Med Surg. 2010;12(1):43–54. 10.1016/j.jfms.2009.12.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tandon R, Cattori V, Gomes-Keller MA, Meli ML, Golder MC, Lutz H, et al. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J Virol Methods. 2005;130(1–2):124–32. 10.1016/j.jviromet.2005.06.017 [DOI] [PubMed] [Google Scholar]
  • 11.Lau SK, Woo PC, Yeung HC, Teng JL, Wu Y, Bai R, et al. Identification and characterization of bocaviruses in cats and dogs reveals a novel feline bocavirus and a novel genetic group of canine bocavirus. J Gen Virol. 2012;93(Pt 7):1573–82. 10.1099/vir.0.042531-0 [DOI] [PubMed] [Google Scholar]
  • 12.Piewbang C, Kasantikul T, Pringproa K, Techangamsuwan S. Feline bocavirus-1 associated with outbreaks of hemorrhagic enteritis in household cats: potential first evidence of a pathological role, viral tropism and natural genetic recombination. Sci Rep. 2019;9(1):16367 10.1038/s41598-019-52902-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. New Engl J Med. 2003;348(20):1953–66. 10.1056/NEJMoa030781 [DOI] [PubMed] [Google Scholar]
  • 14.VanDevanter DR, Warrener P, Bennett L, Schultz ER, Coulter S, Garber RL, et al. Detection and analysis of diverse herpesviral species by consensus primer PCR. J Clin Microbiol. 1996;34(7):1666–71. 10.1128/JCM.34.7.1666-1671.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tong S, Chern SW, Li Y, Pallansch MA, Anderson LJ. Sensitive and broadly reactive reverse transcription-PCR assays to detect novel paramyxoviruses. J Clin Microbiol. 2008;46(8):2652–8. 10.1128/JCM.00192-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.van Boheemen S, Bestebroer TM, Verhagen JH, Osterhaus ADME, Pas SD, Herfst S, et al. A family-wide RT-PCR assay for detection of paramyxoviruses and application to a large-scale surveillance study. PloS One. 2012;7(4):e34961–e. 10.1371/journal.pone.0034961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mochizuki M, Horiuchi M, Hiragi H, San Gabriel MC, Yasuda N, Uno T. Isolation of canine parvovirus from a cat manifesting clinical signs of feline panleukopenia. J Clin Microbiol. 1996;34(9):2101–5. 10.1128/JCM.34.9.2101-2105.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Piewbang C, Techangamsuwan S. Phylogenetic evidence of a novel lineage of canine pneumovirus and a naturally recombinant strain isolated from dogs with respiratory illness in Thailand. BMC Vet Res. 2019;15(1):300 10.1186/s12917-019-2035-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SDW. Automated Phylogenetic Detection of Recombination Using a Genetic Algorithm. Molecular Biology and Evolution. 2006;23(10):1891–901. 10.1093/molbev/msl051 [DOI] [PubMed] [Google Scholar]
  • 20.Martin DP, Murrell B, Golden M, Khoosal A, Muhire B. RDP4: Detection and analysis of recombination patterns in virus genomes. Virus Evolution. 2015;1(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73(1):152–60. 10.1128/JVI.73.1.152-160.1999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zheng CL, Fu YM, Xu ZX, Zou Y, Deng K. Hepatitis B virus core protein dimer‑dimer interface is critical for viral replication. Mol Med Rep. 2019;19(1):262–70. 10.3892/mmr.2018.9620 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Seligman AM, Wasserkrug HL, Hanker JS. A new staining method (OTO) for enhancing contrast of lipid—containing membranes and droplets in osmium tetroxide—fixed tissue with osmiophilic thiocarbohydrazide(TCH). The Journal of cell biology. 1966;30(2):424–32. 10.1083/jcb.30.2.424 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Tapia JC, Kasthuri N, Hayworth KJ, Schalek R, Lichtman JW, Smith SJ, et al. High-contrast en bloc staining of neuronal tissue for field emission scanning electron microscopy. Nat Protoc. 2012;7(2):193–206. 10.1038/nprot.2011.439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lehmbecker A, Rittinghausen S, Rohn K, Baumgärtner W, Schaudien D. Nanoparticles and pop-off technique for electron microscopy: a known technique for a new purpose. Toxicol Pathol. 2014;42(6):1041–6. 10.1177/0192623313509906 [DOI] [PubMed] [Google Scholar]
  • 26.Piewbang C, Jo WK, Puff C, Ludlow M, van der Vries E, Banlunara W, et al. Canine Bocavirus Type 2 Infection Associated With Intestinal Lesions. Vet Pathol. 2018;55(3):434–41. 10.1177/0300985818755253 [DOI] [PubMed] [Google Scholar]
  • 27.He Q, Hsueh M, Zhang G, Joy DC, Leapman RD. Biological serial block face scanning electron microscopy at improved z-resolution based on Monte Carlo model. Sci Rep. 2018;8(1):12985 10.1038/s41598-018-31231-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Odriozola A, Llodrá J, Radecke J, Ruegsegger C, Tschanz S, Saxena S, et al. High contrast staining for serial block face scanning electron microscopy without uranyl acetate. bioRxiv. 2017:207472. [Google Scholar]
  • 29.Porterfield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A. Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. Journal of virology. 2010;84(14):7174–84. 10.1128/JVI.00586-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bayton WA, Westgarth C, Scase T, Price DJ, Bexfield NH. Histopathological frequency of feline hepatobiliary disease in the UK. J Small Anim Pract. 2018;59(7):404–10. 10.1111/jsap.12810 [DOI] [PubMed] [Google Scholar]
  • 31.Hartmann K. Clinical aspects of feline retroviruses: a review. Viruses. 2012;4(11):2684–710. 10.3390/v4112684 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 1987;235(4790):790 10.1126/science.3643650 [DOI] [PubMed] [Google Scholar]
  • 33.Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50(3):661–2. 10.1002/hep.23190 [DOI] [PubMed] [Google Scholar]
  • 34.Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152(6):1297–309. 10.1053/j.gastro.2017.02.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Pujol FH, Navas M-C, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Letters. 2009;286(1):80–8. 10.1016/j.canlet.2009.07.013 [DOI] [PubMed] [Google Scholar]
  • 36.Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47(6):289–309. 10.1159/000080872 [DOI] [PubMed] [Google Scholar]
  • 37.Simmonds P, Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes. Journal of virology. 2005;79(24):15467–76. 10.1128/JVI.79.24.15467-15476.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Mahgoub S, Candotti D, El Ekiaby M, Allain JP. Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol. 2011;49(1):298–306. 10.1128/JCM.00867-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Liu W, Zhai J, Liu J, Xie Y. Identification of natural recombination in duck hepatitis B virus. Virus Res. 2010;149(2):245–51. 10.1016/j.virusres.2010.02.002 [DOI] [PubMed] [Google Scholar]
  • 40.Lyons S, Sharp C, LeBreton M, Djoko CF, Kiyang JA, Lankester F, et al. Species Association of Hepatitis B Virus (HBV) in Non-Human Apes; Evidence for Recombination between Gorilla and Chimpanzee Variants. PLOS ONE. 2012;7(3):e33430 10.1371/journal.pone.0033430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Piewbang C, Jo WK, Puff C, van der Vries E, Kesdangsakonwut S, Rungsipipat A, et al. Novel canine circovirus strains from Thailand: Evidence for genetic recombination. Sci Rep. 2018;8(1):7524 10.1038/s41598-018-25936-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lefeuvre P, Lett JM, Varsani A, Martin DP. Widely conserved recombination patterns among single-stranded DNA viruses. Journal of virology. 2009;83(6):2697–707. 10.1128/JVI.02152-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kappus MR, Sterling RK. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterology & hepatology. 2013;9(2):123–6. [PMC free article] [PubMed] [Google Scholar]
  • 44.Shang Q, Zhang G, Xu C, Chen CX, Yu JG, Yan CY. [Expression of hepatitis B virus antigen in brain tissue from liver cirrhosis patients with hepatitis B and its significance]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001;15(3):277–9. [PubMed] [Google Scholar]
  • 45.Korba BE, Cote PJ, Wells FV, Baldwin B, Popper H, Purcell RH, et al. Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: molecular virologic features of the liver and lymphoid tissues. Journal of virology. 1989;63(3):1360–70. 10.1128/JVI.63.3.1360-1370.1989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Nakamura I, Nupp JT, Cowlen M, Hall WC, Tennant BC, Casey JL, et al. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: Chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology. 2001;33(2):439–47. 10.1053/jhep.2001.21748 [DOI] [PubMed] [Google Scholar]
  • 47.Dienstag JL. Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection. Springer Seminars in Immunopathology. 1981;3(4):461–72. 10.1007/BF01951493 [DOI] [PubMed] [Google Scholar]
  • 48.Son MS, Yoo JH, Kwon C-I, Ko KH, Hong SP, Hwang SG, et al. Associations of Expressions of HBcAg and HBsAg with the Histologic Activity of Liver Disease and Viral Replication. Gut and liver. 2008;2(3):166–73. 10.5009/gnl.2008.2.3.166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Das P, Ahuja A, Gupta S. Overview of the histopathology of chronic hepatitis B infection. Hepatitis B Annual. 2012;9(1):49–85. [Google Scholar]
  • 50.Huang M, Liu J, Chow M, Zhou X, Han Z, He Z, et al. Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy. Journal of cellular and molecular medicine. 2018;22(3):1675–83. 10.1111/jcmm.13444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Cui W, Deng B, Wang W, Liu P. Graves’ hyperthyroidism accompanied with acute hepatitis B virus infection: an extrahepatic manifestation? Virology Journal. 2016;13(1):80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. Journal of viral hepatitis. 2010;17(2):115–22. 10.1111/j.1365-2893.2009.01168.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Chen L, Wu C, Fan X, Gao J, Yin H, Wang T, et al. Replication and infectivity of hepatitis B virus in HBV-related glomerulonephritis. International Journal of Infectious Diseases. 2009;13(3):394–8. 10.1016/j.ijid.2008.08.014 [DOI] [PubMed] [Google Scholar]
  • 54.Kong D, Wu D, Wang T, Li T, Xu S, Chen F, et al. Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection. International Journal of Infectious Diseases. 2013;17(7):e535–e8. 10.1016/j.ijid.2013.01.017 [DOI] [PubMed] [Google Scholar]
  • 55.Pronier C, Guyader D, Jézequel C, Tattevin P, Thibault V. Contribution of quantitative viral markers to document hepatitis B virus compartmentalization in cerebrospinal fluid during hepatitis B with neuropathies. Journal of neurovirology. 2018;24(6):769–72. 10.1007/s13365-018-0662-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology. 1993;18(4):781–9. 10.1002/hep.1840180406 [DOI] [PubMed] [Google Scholar]
  • 57.Goldsmith CS, Miller SE. Modern Uses of Electron Microscopy for Detection of Viruses. Clinical Microbiology Reviews. 2009;22(4):552–63. 10.1128/CMR.00027-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Kamimura T, Yoshikawa A, Ichida F, Sasaki H. Electron microscopic studies of Dane particles in hepatocytes with special reference to intracellular development of Dane particles and their relation with HBeAg in serum. Hepatology. 1981;1(5):392–7. 10.1002/hep.1840010504 [DOI] [PubMed] [Google Scholar]
  • 59.Sakamoto Y, Yamada G, Mizuno M, Nishihara T, Kinoyama S, Kobayashi T, et al. Full and empty particles of hepatitis B virus in hepatocytes from patients with HBsAg-positive chronic active hepatitis. Lab Invest. 1983;48(6):678–82. [PubMed] [Google Scholar]
  • 60.Watanabe K. Electron microscopic studies of experimental viral hepatitis in mice. II. Ultrastructural changes of hepatocytes associated with virus multiplication. J Electron Microsc (Tokyo). 1969;18(3):173–89. [PubMed] [Google Scholar]
  • 61.Holmes IH, Wark MC, Warburton MF. Is rubella an arbovirus?: II. Ultrastructural morphology and development. Virology. 1969;37(1):15–25. 10.1016/0042-6822(69)90301-8 [DOI] [PubMed] [Google Scholar]
  • 62.Sager G, Gabaglio S, Sztul E, Belov GA. Role of Host Cell Secretory Machinery in Zika Virus Life Cycle. Viruses. 2018;10(10):559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Freiman JS, Jilbert AR, Dixon RJ, Holmes M, Gowans EJ, Burrell CJ, et al. Experimental duck hepatitis B virus infection: Pathology and evolution of hepatic and extrahepatic infection. Hepatology. 1988;8(3):507–13. 10.1002/hep.1840080313 [DOI] [PubMed] [Google Scholar]
  • 64.Korba BE, Gowans EJ, Wells FV, Tennant BC, Clarke R, Gerin JL. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. Virology. 1988;165(1):172–81. 10.1016/0042-6822(88)90670-8 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Haitao Guo

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

24 Aug 2020

PONE-D-20-22914

Insights into the genetic diversity, recombination, and systemic infections with evidence of intracellular maturation of hepadnavirus in cats

PLOS ONE

Dear Dr. Piewbang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 08 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Haitao Guo

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following in the Acknowledgments Section of your manuscript:

[C.P. was supported by the Ratchadapisek Somphot Fund for Postdoctoral Fellowship,

Chulalongkorn University. S.W. is financially afforded by scholarship program for ASEN

countries, Chulalongkorn University. This research was funded by The Thailand Research Fund

(RSA6180034), Grant for Joint Funding of External Research Project, Ratchadaphisek Somphot

Endowment Fund and Veterinary Science Research Fund (RES_61_364_31_037),

Chulalongkorn University, and Veterinary Pathogen Bank, Faculty of Veterinary Science,

Chulalongkorn University.]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 [The author(s) received no specific funding for this work.]

3. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript described the detection of the recently discovered domestic cat hepadnavirus (DCH) in cat sera and cats died from hepatic diseases. The authors obtained and characterized the full-length viral genomes and revealed that nine DCH sequences phylogenetically formed three distinct monophyletic clades. They found a putative DCH recombinant strain. They also performed IHC staining of DCH and showed a wide-spread positivity of DCH in multiple tissues. The writing is clear and the results interesting.

1. Table 1, the viral copy number in various organs would be better presented as copies per milligram or gram of tissue.

2. A polyclonal anti-human HBc was used in the IHC staining. The authors should verify the cross-reactivity and specificity of this antibody to DCH core protein using Western blot.

Reviewer #2: The authors explored the genetic diversity of the recently discovered mammalian hepadnavirus, tentatively named domestic cat hepadnavirus (DCH), among a collection of cat sera and cat tissues using PCR. Their full-length genome characterization of revealed the nine Thai DCH sequences obtained formed three distinct monophyletic clades. They found a putative DCH recombinant strain, suggesting a possible role of recombination in DCH evolution. They also used qPCR to determine the viral genome copy numbers in various organs of the cats with liver diseases and were able to localize the putative viral capsid protein in tissues using a polyclonal antibody against the HBV capsid protein via immunohistochemistry (IHC). In addition to the liver, positive-DCH immunoreactivity was found in various other organs, including kidneys, lung, heart, intestine, brain, and lymph nodes, suggesting possible systemic infection.

This report adds some interesting new information regarding a relatively new mammalian hepadnavirus. I have a couple of questions for the authors.

1. Did the authors ever verify the specificity of the polyclonal antibody against the capsid by western blot analysis? Although the IHC control showed some evidence of specificity, western blot analysis will be more definitive. Inclusion of an alignment of the DCH and HBV capsid protein sequence would also help to evaluate the specificity of the polyclonal antibody.

2. The EM images are rather poor and not definitive. The putative capsids claimed by the authors might be surface antigen spheres, given the reported diameter of 23-25 nm, which is closer to the HBsAg spheres (ca. 22 nm) than the HBV capsids (ca. 30 nm). If feasible, immuno-EM using the cross-reactive capsid antibody would help to identify the capsid particles, which at the same time will also help to verify the specificity of the antibody.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Oct 23;15(10):e0241212. doi: 10.1371/journal.pone.0241212.r002

Author response to Decision Letter 0


23 Sep 2020

Rebuttal response on a revision of PONE-D-20-22914

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thank you for your positive reviews to our manuscript.

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

Response: Thank you for your positive reviews to our manuscript.

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thank you for your positive reviews to our manuscript.

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thank you for your positive reviews to our manuscript.

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript described the detection of the recently discovered domestic cat hepadnavirus (DCH) in cat sera and cats died from hepatic diseases. The authors obtained and characterized the full-length viral genomes and revealed that nine DCH sequences phylogenetically formed three distinct monophyletic clades. They found a putative DCH recombinant strain. They also performed IHC staining of DCH and showed a wide-spread positivity of DCH in multiple tissues. The writing is clear and the results interesting.

1. Table 1, the viral copy number in various organs would be better presented as copies per milligram or gram of tissue.

Response: Thank you for your positive reviews to our manuscript. We have revised the unit of the viral load to per gram of extracted tissue and re-calculated the viral copy number as a revision found in the Table 1. (Page 16, lines 364-365)

2. A polyclonal anti-human HBc was used in the IHC staining. The authors should verify the cross-reactivity and specificity of this antibody to DCH core protein using Western blot.

Response: Thank you for your concern and suggestion. We have tested the cross-reactivity of the anti-HBcAg antibody with the DCH-positive samples, compared to the result of HBV-infected tissue using western blot analysis. Furthermore, we have provided the specificity of the antibody by performing the western blotting with the extracted protein derived from DCH-negative liver samples (from cats with/without hepatitis). The details and results of the western blotting were given in the Methods (page 10, lines 221-241) and Results section (pages 19-20, lines 454-469), respectively.

Reviewer #2: The authors explored the genetic diversity of the recently discovered mammalian hepadnavirus, tentatively named domestic cat hepadnavirus (DCH), among a collection of cat sera and cat tissues using PCR. Their full-length genome characterization of revealed the nine Thai DCH sequences obtained formed three distinct monophyletic clades. They found a putative DCH recombinant strain, suggesting a possible role of recombination in DCH evolution. They also used qPCR to determine the viral genome copy numbers in various organs of the cats with liver diseases and were able to localize the putative viral capsid protein in tissues using a polyclonal antibody against the HBV capsid protein via immunohistochemistry (IHC). In addition to the liver, positive-DCH immunoreactivity was found in various other organs, including kidneys, lung, heart, intestine, brain, and lymph nodes, suggesting possible systemic infection.

This report adds some interesting new information regarding a relatively new mammalian hepadnavirus. I have a couple of questions for the authors.

1. Did the authors ever verify the specificity of the polyclonal antibody against the capsid by western blot analysis? Although the IHC control showed some evidence of specificity, western blot analysis will be more definitive. Inclusion of an alignment of the DCH and HBV capsid protein sequence would also help to evaluate the specificity of the polyclonal antibody.

Response: Thank you for your positive review on our manuscript. As your suggestion, we have further elucidated the cross-reactivity throughout the specificity of the antibody used for IHC analysis by using the western blotting. Details and results of the western blotting were described in the Methods (page 10, lines 221-241) and Results section (pages 19-20, lines 454-469), respectively.

2. The EM images are rather poor and not definitive. The putative capsids claimed by the authors might be surface antigen spheres, given the reported diameter of 23-25 nm, which is closer to the HBsAg spheres (ca. 22 nm) than the HBV capsids (ca. 30 nm). If feasible, immuno-EM using the cross-reactive capsid antibody would help to identify the capsid particles, which at the same time will also help to verify the specificity of the antibody.

Response: We sincerely respected with this comment since the EM images are quite not definitive. With the respects of TEM performing on the dead animals and fixative agents are not definitively appropriated for TEM analysis, resulting in poor-defined images. However, we performed the TEM from the FFPE section by locating the areas that were positive to the IHC analysis using Pop-off technique, supporting the particles found in those areas would be the targeting virus. With the respect of reviewer’s concern, we have revised that the detected particles would be the surface antigen spheres as suggestion by reviewer and also added further image of the EM. We honestly said that we are not able to do the immune-EM in this recent and we have performed the western blotting to test the specificity of the antibody used for IHC as described in Methods and Results sections.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Response: We respected with the reviewer’s decision.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Haitao Guo

12 Oct 2020

Insights into the genetic diversity, recombination, and systemic infections with evidence of intracellular maturation of hepadnavirus in cats

PONE-D-20-22914R1

Dear Dr. Piewbang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Haitao Guo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Haitao Guo

14 Oct 2020

PONE-D-20-22914R1

Insights into the genetic diversity, recombination, and systemic infections with evidence of intracellular maturation of hepadnavirus in cats

Dear Dr. Piewbang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Haitao Guo

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw image

    (PDF)

    S1 Table. The DCH-specific primers used for the full-length genome characterization.

    The primers were designed based on an alignment of the three DCH genomes that were available in GenBank.

    (PDF)

    S1 File. Amplification protocols used for characterization of the full-length DCH genome.

    The PCR amplifications were performed using the primers described in S1 Table.

    (PDF)

    S2 File. Automated IHC protocol for DCH detection in FFPE tissues of DCH-PCR positive moribund cats.

    (PDF)

    S1 Fig. Negative controls for the DCH IHC staining.

    No reaction is present within an incubation of normal rabbit IgG antibody NI01control in the (A) liver, (B) kidney, (C) lung, and (D) heart sections of cat no. 3, the (E) intestine of cat no. 2, and (F) brain of cat no. 1.

    (TIF)

    S2 Fig. Domestic cat hepadnavirus particles in cytoplasm of the lung tissue.

    Representative TEM image showing the ultrastructure of the bronchial epithelium and the diffuse electron-dense particles in the cytoplasm (inset). Bar indicates as in figure.

    (TIF)

    S3 Fig. Domestic cat hepadnavirus particles in nucleus of the lung tissue.

    Representative TEM image showing the ultrastructure of the bronchial glandular epithelium and the focal cluster of electron-dense particles in the nucleus (inset). Bar indicates as in figure.

    (TIF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    DCH sequences have been deposited in NCBI GenBank under accession numbers MT506039-MT506047. All other relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES